Status and phase
Conditions
Treatments
About
Pregnant women are vulnerable to malaria, with significant implications both for their health and for the pregnancy. Sulfadoxine-pyrimethamine (SP) is currently the first line drug for the treatment of malaria in pregnancy in Tanzania and surrounding countries, but resistance is emerging rapidly. Alternative drugs must be found, and new drugs and drug combinations are being recommended by many for deployment as first line treatment at the point that SP resistance forces a policy change. However, there are few data on the safety and efficacy of these combinations in pregnant women. This randomised trial aims to assess efficacy and safety, including birth outcome, in pregnant women with malaria in the second or third trimesters. A total of 900 pregnant women will be randomised either to standard treatment (SP) or to one of three potential drugs, or drug combinations recently recommended by a WHO expert panel. These will be SP-amodiaquine, chlorproguanil-dapsone (Lapdap), and amodiaquine-artesunate. Primary outcome will be treatment failure. Secondary outcomes will include 28 day slide clearance, maternal side effects, foetal viability and birth outcome.
Full description
The objectives of this study are to assess the therapeutic efficacy and safety of SP as the current first line drug, and three other potential alternative combinations in treating uncomplicated falciparum malaria during pregnancy, in an area with appreciable levels of SP resistance and rising HIV seroprevalence. Specifically the study will compare the clinical and parasitological response to and the side effects of the following drug regimes:
TRIAL DESIGN
Primary end point
The primary end-point of the trial will be treatment failure. This will be defined as:-
Any of:
Secondary endpoints
Secondary endpoints will include the following:-
The trial
Pregnant women with mild-moderate, slide proven, falciparum malaria will be recruited from the Antenatal wing (ANC) of the Maternal and Child Health (MCH) clinic at Muheza (Teule) Hospital. Pregnant women from Muheza Township and surrounding villages attend this clinic. Nurses attending the clinic will interview all febrile women and women with a recent (past 24 hours) history of fever and those with a probable diagnosis of malaria will be referred to the study team. Those with signs/symptoms of mild-moderate anaemia will also be referred. All referrals will be re-interviewed and examined by the Medical Officer of the study team to exclude concomitant infection(s). Duplicate thick and thin blood smears will be made, Giemsa stained at pH 7.2, and examined microscopically. The consent form will be administered to those meeting the inclusion criteria and they will be enrolled upon consenting.
Inclusion criteria
A pregnant woman who has:-
either a positive blood smear for P.falciparum with at least 1000 asexual parasites/uL in an asymptomatic woman or any of the following symptoms within 2 days prior to consultation: history of fever; headache, vomiting, chills/rigors, and/or any of the following signs: temperature >37.50C and <39.50C, Hb >5 and <9 g/dl) together with P.falciparum parasitaemia at any density
and (in both cases) the following:
Those > 34 weeks are excluded because they are close to term and may deliver during the 28 day follow up period.
Exclusion criteria
Exclusion criteria include:-
Patients with malaria who do not enter the trial because they fulfil an exclusion criterion will be treated in the optimum way decided by the attending physician. In general, those with severe disease will receive parenteral quinine whilst those with mild disease will receive SP.
Withdrawal criteria
Withdrawal criteria will include:-
withdrawal of consent or non-compliance with assigned study regimen;
appearance of other species of Plasmodium;
vomiting within one hour after re-dosing;
protocol violation.
If it is necessary to withdraw a patient during the treatment phase, administration of the study drug will be discontinued. If the patient is still parasitaemic, quinine will be given as a rescue therapy unless there are clinical reasons to use another drug. For withdrawals outside the treatment phase the team will carry out all the safety and efficacy assessment measurements that would have been carried out at the next scheduled visit and the same will apply at delivery (unless the patient is lost to follow up).
Patients who fail on treatment will be treated with rescue treatment and counted as treatment failures (see above).
TREATMENT OF PATIENTS
Study regimens
Study drugs will be purchased or sourced from reputable sources with Good Manufacturing Practice (GMP). Dosages will be based on the body weight (kg) of the patient and the schedule will be as below.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
A pregnant woman who has either a positive blood smear for P.falciparum with at least 1000 asexual parasites/uL in an asymptomatic woman
or any of the following symptoms within 2 days prior to consultation:
and (in both cases) the following:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal